With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by Royal Bank of Canada from $402.00 to $407.00 in a research note issued to investors on Tuesday,Benzinga reports.

Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Berkshire, along with most other institutional investors, will disclose its equity holdings for U.S-listed companies in a 13-F filing with the Securities and Exchange Commission.

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Shares of Vertex Pharmaceuticals Inc. VRTX slid 1.49% to $481.16 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.36% to ...

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

One headwind that could slow the uptake of the Vertex pain drug, though, is cost. The list price is $15.50 per pill ... opioid if given the choice. Vertex stock today trades for about 24x forward ...

Vertex's stock price has shown resilience, with a year-to-date performance of +22% as of September 2024. This growth has positioned the company as a potential value name in the biotech sector, ...

Morgan Stanley upped their target price on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th.

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a ... That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about ...